ur-63325
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01260753)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histamine H4 receptorANTAGONIST
HRH4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CNC1CN(c2cc(N)nc(CC(C)C)n2)C1- Mol. weight
- 235.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314396 ↗
- ChEMBLCHEMBL3545345 ↗
Also known as
- ur-63325
- ur-63325
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01260753 | Phase 2 | Dec 1, 2010 | Palau Pharma S.A., Parexel |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Palau Pharma S.A. | For profit | 1 | 1 | 1 | 2010 |
| Parexel | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1